Business Wire

CORRECTING and REPLACING MultiSafepay Supporting 20,000 SMEs to Scale Through Payment Integration and Digitisation with Antom Technology Engine

17.4.2025 15:36:00 CEST | Business Wire | Press release

Share

MultiSafepay, the Amsterdam-based digital payment provider, now serves 20,000+ SME merchants across Europe, with merchant numbers growing 11% since its strategic integration with Antom, empowering thousands of businesses to thrive. Transaction volumes have surged, growing by 44% YoY, driven organically by rapid deployment of POS solutions and collaboration with Antom. Ant International has opened a new office in Amsterdam’s City Centre for MultiSafepay which enables more efficient collaboration with Ant International’s other business pillars.

Seventh paragraph, first sentence should read: Today, 8% of MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technology (such as C-TAP terminals) as well as Smart POS devices which offer merchants digital tools and do more than just accept payments. (instead of MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technology (such as C-TAP terminals) as well as Smart POS devices which offer merchants digital tools and do more than just accept payments.).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417858076/en/

Ant International’s new office in Amsterdam City Centre will house MultiSafepay’s operations and enable further collaboration between its business pillars.

The updated release reads:

MULTISAFEPAY SUPPORTING 20,000 SMES TO SCALE THROUGH PAYMENT INTEGRATION AND DIGITISATION WITH ANTOM TECHNOLOGY ENGINE

  • MultiSafepay, the Amsterdam-based digital payment provider, now serves 20,000+ SME merchants across Europe, with merchant numbers growing 11% since its strategic integration with Antom, empowering thousands of businesses to thrive.
  • Transaction volumes have surged, growing by 44% YoY, driven organically by rapid deployment of POS solutions and collaboration with Antom.
  • Ant International has opened a new office in Amsterdam’s City Centre for MultiSafepay which enables more efficient collaboration with Ant International’s other business pillars.

MultiSafepay (MSP), an Amsterdam-based payment service provider, which became part of Ant International’s Antom, reported strong growth since its strategic integration with Antom, supporting thousands more SMEs in Europe to scale through innovative solutions.

Since announcing its acquisition in July 2024, MSP has expanded its merchant base across Europe to 20,000+, an 11% increase. Transaction volumes surged by 44% year-on-year, reflecting customers' robust business growth as well as the addition of new top industry performers. Merchants are increasingly moving to unified payment services, in-person payments are now already at 8% of total volume processed across retail and food & beverage verticals - demonstrating the value of increased efficiency in operations and the benefits of enhancing customer touchpoints.

This acceleration displays the potential of Antom’s post-acquisition strategy to combine local expertise with a global technology suite, benefiting the merchants MSP serves with innovative digital technologies.

MSP provides merchants with unified payment capabilities, supporting more than 40 local and international payment methods, including cards, e-wallets, Buy Now Pay Later, internet banking, across in-person and online channels.

Since becoming wholly-owned subsidiary of Ant International, MSP has been integrating with Antom to help businesses improve operations, and scale with confidence, using the powerful solutions relied on by industry leaders globally. MSP will also look to work with other businesses of Ant International such as WorldFirst to offer inclusive financial services to its SME merchant base.

In under a year, the integration has propelled innovation for merchant expansion, improvements in payment success rates, and infrastructure upgrades, demonstrating the power of combining MSP’s 25-years of expertise with Antom’s global experience.

Today, 8% of MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technology (such as C-TAP terminals) as well as Smart POS devices which offer merchants digital tools and do more than just accept payments. Supporting a range of technology gives merchants a flexible, cost-effective way to handle payments and demonstrates MSP’s dedication to helping small businesses thrive by offering a solution that fits their unique needs.

Olaf Geurs, CEO of MultiSafepay, commented: “We expect to exceed our 2025 growth projections given current strong numbers and deepened partnership with Ant International. The data shows how SME partners are embracing our joint innovative solutions with Antom to accelerate their digital operations. MultiSafepay's momentum underscores the value of our collaboration in empowering businesses to succeed in today's fast-evolving world.”

“Accelerating the adoption of new technologies like AI in merchant payment services enable us to raise efficiency while maximizing our expertise in the SME sector,” said Gary Liu, General Manager of Antom, Ant International. “By building on MultiSafepay’s platform and Antom’s global expertise, we’re making simple, flexible payments accessible to every business - no matter their size or ambition.”

The company has recently moved to Ant International’s new office in Amsterdam’s vibrant City Centre, enabling collaborations with other Ant International business pillars to directly benefit SMEs.

About Antom

Ant International's Antom is the leading payment and digitisation services provider for merchants around the world. It offers unified merchant payment solutions to serve businesses of all sizes. Antom supports merchants in over 50 countries and regions, enabling them to connect with consumers in more than 200 markets, with the flexibility to accept payments in more than 100 currencies. Beyond payments, it provides digital marketing solutions and merchant digitisation services to help merchant streamline operations and enhance customer engagement.

To learn more, please visit https://www.antom.com/.

About MultiSafepay

MultiSafepay is a leading Amsterdam-based payment service provider, combining decades of expertise with powerful in-house technology to help every business grow faster and compete with confidence, no matter their size or ambition.

By leveling the playing field in payments, we offer European businesses a simple, flexible solution for online, in-person, and unified payments, all through a single platform and integration. With a personal approach to payments, we optimize success rates, reduce complexity, and help your business do more, and earn more.

https://www.multisafepay.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250417858076/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye